pocketful logo light
pocketful logo light
Beryl Drugs Ltd logo

Beryl Drugs Ltd

NSE: BSE: 524606

₹20.84

(4.99%)

Sun, 31 May 2026, 01:55 am

mtf coin illustrationMTF 5x

Beryl Drugs Share Price Live Chart

1 Day

(4.99%)

No Result Found

Summary

  • Market Cap

    10.57

  • Net Profit

    0.58

  • P/B

    1.13

  • Sector P/E

    44.89

  • P/E

    18.46

  • EV/EBITDA

    5.24

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    6.30

  • ROCE

    9.93

  • Debt/Equity

    0.50

  • EPS (TTM)

    0.03

  • Dividend Yield

    0

  • Book Value

    18.63

  • Interest Cover

    2.61

Analysis

all

thumbs up icon

Pros

  • Beryl Drugs is profitable, therefore cash runway is not a concern.
  • Beryl Drugs is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (95.6%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 1.5x debt.
  • Beryl Drugs's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to evaluate Beryl Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Beryl Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Beryl Drugs's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • The level of debt compared to net worth has increased over the past 5 years (25.7% vs 47% today).
  • Beryl Drugs's level of debt (47%) compared to net worth is high (greater than 40%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters27.4826.3826.3826.3826.38
FII00000
DII00000
Public72.5273.6273.6273.6273.62
Government00000

Read More

Technical Analysis

RSI

50.07

MACD

-0.57

50 DMA

21.38

200 DMA

22.22

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic40.3931.3526.5822.3117.5413.274.23
Fibonacci31.3527.9025.7722.3118.8616.7313.27
Camarilla24.2923.4622.6322.3120.9720.1419.31

Pivots Level: Classic

R3

+18.08

40.39

R2

+9.04

31.35

R1

+4.26

26.58

22.31
22.31
Pivot Point
LTP: 20.84

S1

-4.78

17.54

S2

-9.04

13.27

S3

-18.08

4.23

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    20.14

  • 20-EMA

    20.60

  • 30-EMA

    20.90

  • 50-EMA

    21.19

  • 100-EMA

    21.57

  • 200-EMA

    22.36

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
28 May 2026board-meetingsAccounts
01 Apr 2026egm
09 Feb 2026egm
09 Feb 2026board-meetingsQuarterly Results, EGM
13 Nov 2025board-meetingsQuarterly Results
02 Sept 2025agm
09 Sept 2024agm
25 Aug 2023agm
02 Sept 2022agm
03 Sept 2021agm

Read More

Peer Comparison

Beryl Drugs Ltd logo

Beryl Drugs Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Beryl Drugs Ltd About

Beryl Drugs is principally engaged in manufacturing of bulk drugs

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1993

Headquarters

CEO

Sudhir Sethi

Employees

Contact

Website icon

Website

http://www.beryldrugs.com

Email icon

Email

beryldrugs25@yahoo.com

Phone icon

Phone

91-731-25076375/3046366

Location icon

Location

133 Kanchan Bag, , Indore, Madhya Pradesh, 452001

Read More

Beryl Drugs Ltd Company History

YearHistory
1994
  • The company was incorporated as a medicine pharmaceutical manufacturer.
2007
  • The board of directors decided to issue 1.50 million equity shares and 2 million warrants to promoters and strategic investors on a preferential basis.
  • The authorized share capital was increased from Rs 5.50 crores to Rs 10.00 crores.
2008
  • The board of directors approved the issue of 35 lacs warrants to promoters and strategic investors on a preferential basis.
2015
  • Beryl Drugs and MPPHSCL signed a deal worth Rs 11.8 crores.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
PRADEEP KUMAR JAINbulkBuy3000026.108 Apr 2026
SAMIR NARENDRA GUPTAbulkSell9992122.516 Dec 2025
PRADEEP KUMAR JAINbulkBuy10000022.516 Dec 2025
SAMIR NARENDRA GUPTAbulkBuy10000124.8528 Feb 2025
NARENDRAKUMAR BHAGWANDAS GUPTAbulkSell10000024.8528 Feb 2025
NARENDRAKUMAR BHAGWANDAS GUPTAbulkSell3803843.2309 Sept 2024
NARENDRAKUMAR BHAGWANDAS GUPTAbulkSell7447538.606 Sept 2024
KRUNALKUMAR KANUJI THAKORbulkSell3698041.4710 Jun 2024
KRUNALKUMAR KANUJI THAKORbulkBuy2389341.5710 Jun 2024
HINDON TRADERS & BROKERS PRIVATE LIMITEDbulkSell8500028.5201 Apr 2024

Read More

Beryl Drugs Ltd News

Beryl Drugs approves FY26 audited results

Beryl Drugs Limited board approved audited financial statements for FY26 on May 28, 2026. The meeting also took on record the statutory auditor's report.

28 May 2026

companies

Beryl Drugs Board Meeting on May 28

Beryl Drugs Limited has scheduled a board meeting for May 28, 2026, to consider audited financial results for FY26.

20 May 2026

companies

Beryl Drugs EGM Approves Rs. 5 Cr RPT and Director Appointments

Beryl Drugs' EGM on May 11, 2026 approved three resolutions: regularisation of Mr. Shailendra Pathak as WTD, appointment of Mrs. Neha Sarda as Independent Director, and a Rs. 5 Cr RPT with Aminova Infusions.

13 May 2026

companies

Beryl Drugs EGM Approves Rs. 5 Cr RPT with Aminova Infusions

Beryl Drugs' EGM on May 11, 2026 approved a Rs. 5 Cr material related party transaction with Aminova Infusions Pvt. Ltd. for product distribution in Maharashtra, Gujarat, and export markets.

11 May 2026

companies

Beryl Drugs EGM Regularises Pathak & Sarda as Directors

Beryl Drugs EGM on May 11, 2026 regularised Shailendra Pathak as Whole-Time Director for 5 years and Neha Sarda as Independent Director for 5 years from May 11, 2026.

11 May 2026

companies

Read More